Ausgabe 3/2016
Inhalt (23 Artikel)
Editorial
Editorial
Therapeutic drug monitoring of 5-fluorouracil
James J. Lee, Jan H. Beumer, Edward Chu
Pharmacokinetic variations in cancer patients with liver dysfunction: applications and challenges of pharmacometabolomics
Ali Aboel Dahab, Dhia El-Hag, Gamal M. Moutamed, Sarah Aboel Dahab, Ramadan Abuknesha, Norman W. Smith
Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours
Amita Patnaik, Anthony Tolcher, Kyriakos P. Papadopoulos, Murali Beeram, Drew Rasco, Theresa L. Werner, John W. Bauman, Anita Scheuber, Donna S. Cox, Bela R. Patel, YanYan Zhou, Mohammed Hamid, Daniel Schramek, Sunil Sharma
A multicenter phase II trial of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer
Kazuhiko Yamada, Masao Ichiki, Kazuhisa Takahashi, Yasushi Hisamatsu, Hiroaki Takeoka, Koichi Azuma, Takehito Shukuya, Kazuo Nishikawa, Takaaki Tokito, Hidenobu Ishii, Tomoaki Hoshino
Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients
Ankit Madan, Benjamin S. Jones, Rodolfo Bordoni, Mansoor N. Saleh, Mary S. Jerome, Deborah K. Miley, Bradford E. Jackson, Francisco Robert
Effects of a bolus injection of 5-fluorouracil on dihydropyrimidine dehydrogenase activity in rats receiving continuous infusion of 5-fluorouracil
Shinji Kobuchi, Asuka Hayashi, Mayu Taniguchi, Yukako Ito, Takao Tamura, Toshiyuki Sakaeda
Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours
Kan Yonemori, Kenji Tamura, Makoto Kodaira, Koshi Fujikawa, Tamotsu Sagawa, Taito Esaki, Tsuyoshi Shirakawa, Fumihiko Hirai, Yuki Yokoi, Toshio Kawata, Ben Hatano, Yasuo Takahashi
SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia
Jeong-Hyun Kim, Chansu Lee, Hyun Sub Cheong, Youngil Koh, Kwang-Sung Ahn, Hyung-Lae Kim, Hyoung Doo Shin, Sung-Soo Yoon
A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer
D. J. Renouf, D. Hedley, M. K. Krzyzanowska, M. Schmuck, L. Wang, M. J. Moore
Ethnic sensitivity assessment of the antibody–drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer
Chunze Li, Bei Wang, Dan Lu, Jin Y. Jin, Yuying Gao, Kiyoshi Matsunaga, Yuriko Igawa, Ihsan Nijem, Michael Lu, Alexander Strasak, Nataliya Chernyukhin, Sandhya Girish
Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network
Sumitra Shantakumar, Beth L. Nordstrom, Luc Djousse, Susan A. Hall, David R. Gagnon, Kathy H. Fraeman, Myrthe van Herk-Sukel, Karen Chagin, Jeanenne Nelson
A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab
Naoki Takahashi, Satoru Iwasa, Masaru Fukahori, Kazuki Sudo, Yusuke Sasaki, Hirokazu Shoji, Yoshitaka Honma, Natsuko Tsuda Okita, Atsuo Takashima, Tetsuya Hamaguchi, Narikazu Boku, Yasuhiro Shimada, Kazufumi Honda, Tesshi Yamada, Yasuhide Yamada
A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer
Muhammad S. Beg, Nilofer S. Azad, Sandip P. Patel, Jose Torrealba, Sharon Mavroukakis, Melony A. Beatson, Xue Ping Wang, Philip M. Arlen, Michael A. Morse
Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study)
Takao Takahashi, Yasunori Emi, Eiji Oki, Kazuma Kobayashi, Akihito Tsuji, Mototsugu Shimokawa, Takaho Tanaka, Yoshito Akagi, Yutaka Ogata, Hideo Baba, Kazuhiro Yoshida, Shoji Natsugoe, Yoshihiko Maehara
Protein expression of ATP-binding cassette transporters ABCC10 and ABCC11 associates with survival of colorectal cancer patients
V. Krizkova, M. Dubova, S. Susova, O. Vycital, J. Bruha, M. Skala, V. Liska, O. Daum, P. Soucek
Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline
Laurent Claret, Jenny Zheng, Francois Mercier, Pascal Chanu, Ying Chen, Brad Rosbrook, Pithavala Yazdi, Peter A. Milligan, Rene Bruno
The molecular mechanism of action of superactive human leptin antagonist (SHLA) and quadruple leptin mutein Lan-2 on human ovarian epithelial cell lines
Elżbieta Fiedor, Ewa Łucja Gregoraszczuk
BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen
Jung-woo Chae, Yi Ling Teo, Han Kiat Ho, Jaeyeon Lee, Hyun-moon Back, Hwi-yeol Yun, Mats O. Karlsson, Kwang-il Kwon, Alexandre Chan
Myelosuppression by chemotherapy in obese patients with gynecological cancers
Kensuke Kamimura, Yoshifumi Matsumoto, Qiliang Zhou, Masato Moriyama, Yasuo Saijo
SM-1, a novel PAC-1 derivative, activates procaspase-3 and causes cancer cell apoptosis
Yanfen Chen, Meng Sun, Jingsong Ding, Qubo Zhu
Repression of phosphoglycerate dehydrogenase sensitizes triple-negative breast cancer to doxorubicin
Xia Zhang, Weijun Bai